IFNA1 and Dravet syndrome: JAK inhibition, which targets downstream effects of IFN activation, also showed phenotypic improvement in mouse models of DS (Chi et al., 2023; Galbraith et al., 2023; Tuttle et al., 2020), and a clinical trial examining the JAK inhibitor tofacitinib in individuals with DS showed promise for alleviating autoimmune-related skin conditions (Rachubinski et al., 2024).